Career history
In the news
- Today, our CEO, Kristof Van Emelen, took the stage at BioCentury Inc. Grand Rounds: Europe to present Obulytix’s work on Precision Lysin Therapeutics (PLTs), a novel modality addressing one of today’s most pressing issues, antibiotic resistance. Capable of fast killing under real world conditions, PLTs present a transformational solution that delivers meaningful efficacy without fueling resistance. #Obulytix #AMR #AntimicrobialResistance #Biotech #DrugDevelopment #LifeSciences #PrecisionLysinTherapeutics #BioCenturyGrandRounds
- Next week, Obulytix is on the move. 🌍 From Amsterdam to Lisbon and Boston, members of our team will be connecting with the international biotech and #AMR community, while our colleagues in #Ghent continue to move our science forward in the lab. Amsterdam 🇳🇱 Kristof Van Emelen and Henrik Luessen are excited to be presenting our science at the 2nd BioCentury Inc. Grand Rounds Steering Committee, which connects translational science with the right partners to advance drug development. Lisbon 🇵🇹 Guy Hermans will attend @GAMRIC
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.